Mouse monoclonal antibody to 1
4.3.3 protein eta【3G12]: Purified/Mouse monoclonal antibody to 14.3.3 protein eta【3G12]: Purified/Mouse monoclonal antibody to 14.3.3 protein eta【3G12]: Purified- 询价
- Biosensis
- 澳大利亚
- M-1572-100-E
- 2025年07月13日
- Mouse monoclonal antibody to 14.3.3 protein eta【3G12]: Purified
- 小鼠
- Mouse monoclonal antibody to 14.3.3 protein eta【3G12]: Purified
企业认证
相关产品推荐更多 >
TCEB3B MaxPab小鼠源多克隆抗体(B01) | TCEB3B MaxPab mouse polyclonal antibody (B01)
询价
Transducin Like Enhancer Of Split 4 (TLE4) Antibody (FITC)/Transducin Like Enhancer Of Split 4 (TLE4) Antibody (FITC)/Transducin Like Enhancer Of Split 4 (TLE4) Antibody (FITC)
询价
AF555 Anti-human CD122 Antibody *TU27*/AF555 Anti-human CD122 Antibody *TU27*/AF555 Anti-human CD122 Antibody *TU27*
询价
Enapotamab (AXL) 抗体, 单克隆-Enapotamab (AXL) Antibody, Monoclonal
￥22
PKA 2 beta Antibody/PKA 2 beta Antibody/PKA 2 beta Antibody
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Full length recombinant 14.3.3 protein ETA expressed in and purified from E. coli.
- 亚型：
Mouse monoclonal antibody to 14.3.3 protein eta【3G12]: Purified
- 形态：
Mouse monoclonal antibody to 14.3.3 protein eta【3G12]: Purified
- 保存条件：
厂家建议常温运输。冻干粉抗体溶解之后，建议分装保存于-20℃。请避免反复冻融。
- 克隆性：
单克隆
- 标记物：
Mouse monoclonal antibody to 14.3.3 protein eta【3G12]: Purified
- 适应物种：
Mouse monoclonal antibody to 14.3.3 protein eta【3G12]: Purified
- 保质期：
根据订购时间与产品批次判定，欢迎联系艾美捷咨询确认
- 抗原来源：
小鼠
- 目录编号：
Mouse monoclonal antibody to 14.3.3 protein eta【3G12]: Purified
- 级别：
一抗
- 库存：
小鼠来源毒性抗体：14.3.3蛋白eta【3G12】：纯化
- 供应商：
艾美捷
- 宿主：
小鼠
- 应用范围：
Mouse monoclonal antibody to 14.3.3 protein eta【3G12]: Purified
- 浓度：
Mouse monoclonal antibody to 14.3.3 protein eta【3G12]: Purified
- 靶点：
Mouse monoclonal antibody to 14.3.3 protein eta【3G12]: Purified
- 抗体英文名：
Mouse monoclonal antibody to 14.3.3 protein eta【3G12]: Purified
- 抗体名：
小鼠来源毒性抗体：14.3.3蛋白eta【3G12】：纯化
- 规格：
100ug
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
Introduction of human 14-3-3 proteins
of the tryptic peptides derived from the purified enzyme revealed two amino acid sequences homologous to the 14-3-3 proteins.A polyclonal antibody was raised against purified ST-IV.A 33 kDa protein was co-immunoprecipitated from rat brain extracts with the anti
The production of monoclonal antibody by hybridoma
, A., Popkov, M., Cortez, X., Fuller, R., Elia, M., Kerwin, L., and C.F. Barbas III. (2003) Rapid monoclonal antibody generation via dendritic cell targeting in vivo. Hybridoma and Hybridomics 22 (1), 23-31.
技术资料暂无技术资料 索取技术资料
